Logo

AXGN

AxoGen, Inc.

AXGN

AxoGen, Inc. • NASDAQ
$28.65 ▲ 0.35% (+0.10)
Market Cap $1.32 B
52w High $28.99
52w Low $9.22
Dividend Yield 0%
P/E -573
Volume 239.14K
Outstanding Shares 45.98M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $60.082M ▲ $44.081M ▲ $708K ▲ 1.178% ▲ $0.02 ▲ $12.649M ▲
Q2-2025 $56.662M ▲ $40.346M ▲ $579K ▲ 1.022% ▲ $0.013 ▲ $4.376M ▲
Q1-2025 $48.56M ▼ $36.594M ▲ $-3.834M ▼ -7.895% ▼ $-0.085 ▼ $298K ▼
Q4-2024 $49.405M ▲ $35.558M ▼ $450K ▲ 0.911% ▲ $0.01 ▲ $4.165M ▲
Q3-2024 $48.644M $36.754M $-1.858M -3.82% $-0.042 $2M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $23.902M ▼ $216.4M ▲ $95.595M ▲ $120.805M ▲
Q2-2025 $35.922M ▲ $205.453M ▲ $93.177M ▲ $112.276M ▲
Q1-2025 $22.069M ▼ $196.165M ▼ $90.8M ▼ $105.365M ▲
Q4-2024 $33.482M ▲ $203.728M ▲ $99.821M ▲ $103.907M ▲
Q3-2024 $24.53M $191.985M $92.578M $99.407M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $708K ▲ $3.223M ▼ $-3.751M ▲ $2.394M ▲ $1.866M ▼ $1.358M ▼
Q2-2025 $579K ▲ $7.73M ▲ $-6.947M ▼ $1.157M ▼ $1.94M ▲ $7.008M ▲
Q1-2025 $-3.834M ▼ $-13.179M ▼ $1.339M ▲ $2.382M ▲ $-9.458M ▼ $-13.435M ▼
Q4-2024 $450K ▲ $8.735M ▲ $-813K ▲ $970K ▲ $8.892M ▲ $7.922M ▲
Q3-2024 $-1.858M $3.901M $-5M $572K $-527K $2.763M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily over the past several years, and gross profits are rising alongside it. At the same time, operating losses have narrowed and the business is hovering close to break-even on an operating basis. However, bottom-line profits are still negative, meaning the company is not yet consistently profitable. Overall, the trend is one of improving economics and better cost control, but with clear dependence on continued growth to fully turn the corner into sustained profitability.

Balance Sheet

Balance Sheet The balance sheet looks steady but not especially strong. Total assets and shareholders’ equity have been fairly stable, suggesting the company is growing in a measured way rather than rapidly expanding its asset base. Debt has remained at a similar level for several years, which creates ongoing obligations but does not appear to be spiraling higher. Cash on hand is modest, so while the company is not in obvious distress, it does not have an especially large financial cushion and likely needs to manage spending carefully.

Cash Flow

Cash Flow Cash flow has moved from consistently negative toward roughly break-even, which is a meaningful improvement. Operating cash use has shrunk over time, showing that the underlying business is becoming more self-sustaining. Free cash flow is still thin, in part because the company continues to invest in its facilities and infrastructure, though these investments are not unusually large. This pattern suggests a business transitioning from cash-burning growth mode toward a more balanced phase, but still sensitive to any setbacks in revenue or margins.

Competitive Edge

Competitive Edge AxoGen operates in a specialized niche of peripheral nerve repair, where it has established itself as an early mover and recognized leader in processed nerve allografts. Its flagship Avance nerve graft and AxoGuard product family give surgeons a broad toolkit that many competitors do not match, helping the company build strong relationships and brand recognition in nerve repair. Extensive clinical data and real-world registry results provide an evidence base that is difficult and time-consuming for new entrants to replicate, reinforcing its moat. The pending biologics approval for Avance, if granted, could add a long period of regulatory exclusivity, but this also concentrates risk around a single major regulatory decision.

Innovation and R&D

Innovation and R&D Innovation is a core strength: AxoGen has built a platform of biologically based solutions that differ meaningfully from traditional synthetic conduits and nerve autografts. Recent and upcoming products, such as advanced nerve protectors and soft tissue matrices, extend its reach into more complex injuries and new surgical settings. The company continues to generate clinical data through long-term studies, which supports adoption but also requires ongoing investment. It is also actively exploring new applications in areas like oral surgery, breast reconstruction, and pain procedures, which could broaden its addressable market if surgeons embrace these uses.

Summary

AxoGen combines a clearly differentiated technology position in a focused medical niche with financials that show steady improvement but not yet durable profitability. Revenue growth and narrowing losses indicate that the business model is gaining scale, yet the modest cash cushion and persistent net losses leave the company sensitive to execution and regulatory outcomes. Its competitive moat rests on clinical data, surgeon relationships, and a broad product suite, with the potential biologics approval for Avance acting as a major future swing factor. Overall, this is an innovation-driven medical device and biologics business with meaningful upside potential tied to nerve repair adoption and regulatory milestones, balanced by ongoing financial and regulatory risk.

NEWS

October 29, 2025 · 7:00 AM UTC

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Read more

October 18, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

Read more

October 13, 2025 · 1:42 PM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

Read more

October 8, 2025 · 5:44 PM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

Read more

October 3, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

Read more